Stemedica gets IND approval from Indonesian FDA to initiate Phase II trial to treat AMI
The IND was filed by SCI with support from Stemedica Asia, a subsidiary of Stemedica, and was based on Stemedica’s United States FDA-approved Phase II AMI trial protocol.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.